Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Design Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Design Therapeutics, Inc.’s stock price such as:

• Design Therapeutics, Inc.’s current stock price and volume
• Why Design Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for DSGN from analysts
• DSGN’s stock price momentum as measured by its relative strength

About Design Therapeutics, Inc. (DSGN)

Before we jump into Design Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

Want to learn more about Design Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Design Therapeutics, Inc..

What Caused Design Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 30, 2026, there were 0 analysts who downgraded Design Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Design Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Design Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Design Therapeutics, Inc. (DSGN) by visiting AAII Stock Evaluator.

Relative Price Strength of Design Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 30, 2026, Design Therapeutics, Inc. has a weighted four-quarter relative price strength of 5.20%, which translates to a Momentum Score of 75 and is considered to be Strong.

Want to learn more about how Design Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Design Therapeutics, Inc. Stock Price: Bottom Line

As of October 1, 2026, Design Therapeutics, Inc.’s stock price is $12.480, which is down 0.72% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Design Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.